BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

205 related articles for article (PubMed ID: 26201544)

  • 1. Screening for Lynch syndrome and referral to clinical genetics by selective mismatch repair protein immunohistochemistry testing: an audit and cost analysis.
    Colling R; Church DN; Carmichael J; Murphy L; East J; Risby P; Kerr R; Chetty R; Wang LM
    J Clin Pathol; 2015 Dec; 68(12):1036-9. PubMed ID: 26201544
    [TBL] [Abstract][Full Text] [Related]  

  • 2. BRAF V600E mutation analysis simplifies the testing algorithm for Lynch syndrome.
    Jin M; Hampel H; Zhou X; Schunemann L; Yearsley M; Frankel WL
    Am J Clin Pathol; 2013 Aug; 140(2):177-83. PubMed ID: 23897252
    [TBL] [Abstract][Full Text] [Related]  

  • 3. BRAFV600E immunohistochemistry facilitates universal screening of colorectal cancers for Lynch syndrome.
    Toon CW; Walsh MD; Chou A; Capper D; Clarkson A; Sioson L; Clarke S; Mead S; Walters RJ; Clendenning M; Rosty C; Young JP; Win AK; Hopper JL; Crook A; von Deimling A; Jenkins MA; Buchanan DD; Gill AJ
    Am J Surg Pathol; 2013 Oct; 37(10):1592-602. PubMed ID: 23797718
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Assessment of Tumor Sequencing as a Replacement for Lynch Syndrome Screening and Current Molecular Tests for Patients With Colorectal Cancer.
    Hampel H; Pearlman R; Beightol M; Zhao W; Jones D; Frankel WL; Goodfellow PJ; Yilmaz A; Miller K; Bacher J; Jacobson A; Paskett E; Shields PG; Goldberg RM; de la Chapelle A; Shirts BH; Pritchard CC;
    JAMA Oncol; 2018 Jun; 4(6):806-813. PubMed ID: 29596542
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Universal Versus Targeted Screening for Lynch Syndrome: Comparing Ascertainment and Costs Based on Clinical Experience.
    Erten MZ; Fernandez LP; Ng HK; McKinnon WC; Heald B; Koliba CJ; Greenblatt MS
    Dig Dis Sci; 2016 Oct; 61(10):2887-2895. PubMed ID: 27384051
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Cost-Effectiveness Analysis of Different Genetic Testing Strategies for Lynch Syndrome in Taiwan.
    Chen YE; Kao SS; Chung RH
    PLoS One; 2016; 11(8):e0160599. PubMed ID: 27482709
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Tumor testing to identify lynch syndrome in two Australian colorectal cancer cohorts.
    Buchanan DD; Clendenning M; Rosty C; Eriksen SV; Walsh MD; Walters RJ; Thibodeau SN; Stewart J; Preston S; Win AK; Flander L; Ouakrim DA; Macrae FA; Boussioutas A; Winship IM; Giles GG; Hopper JL; Southey MC; English D; Jenkins MA
    J Gastroenterol Hepatol; 2017 Feb; 32(2):427-438. PubMed ID: 27273229
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Is tumor testing efficiency for Lynch syndrome different in rectal and colon cancer?
    Marabelli M; Gandini S; Rafaniello PR; Calvello M; Tolva G; Feroce I; Lazzeroni M; Marino E; Dal Molin M; Trovato C; Guerrieri-Gonzaga A; Petz WL; Barberis M; Bertario L; Bonanni B
    Dig Liver Dis; 2020 Dec; 52(12):1503-1511. PubMed ID: 32620519
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Costs and outcomes of Lynch syndrome screening in the Australian colorectal cancer population.
    Cenin DR; Naber SK; Lansdorp-Vogelaar I; Jenkins MA; Buchanan DD; Preen DB; Ee HC; O'Leary P
    J Gastroenterol Hepatol; 2018 Oct; 33(10):1737-1744. PubMed ID: 29645364
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Universal screening for Lynch syndrome in a large consecutive cohort of Chinese colorectal cancer patients: High prevalence and unique molecular features.
    Jiang W; Cai MY; Li SY; Bei JX; Wang F; Hampel H; Ling YH; Frayling IM; Sinicrope FA; Rodriguez-Bigas MA; Dignam JJ; Kerr DJ; Rosell R; Mao M; Li JB; Guo YM; Wu XY; Kong LH; Tang JH; Wu XD; Li CF; Chen JR; Ou QJ; Ye MZ; Guo FM; Han P; Wang QW; Wan DS; Li L; Xu RH; Pan ZZ; Ding PR;
    Int J Cancer; 2019 May; 144(9):2161-2168. PubMed ID: 30521064
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Molecular testing for Lynch syndrome in people with colorectal cancer: systematic reviews and economic evaluation.
    Snowsill T; Coelho H; Huxley N; Jones-Hughes T; Briscoe S; Frayling IM; Hyde C
    Health Technol Assess; 2017 Sep; 21(51):1-238. PubMed ID: 28895526
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Comparative effectiveness of screening strategies for Lynch syndrome.
    Barzi A; Sadeghi S; Kattan MW; Meropol NJ
    J Natl Cancer Inst; 2015 Apr; 107(4):. PubMed ID: 25794514
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A prospective, multicenter, population-based study of BRAF mutational analysis for Lynch syndrome screening.
    Bessa X; Ballesté B; Andreu M; Castells A; Bellosillo B; Balaguer F; Castellví-Bel S; Paya A; Jover R; Alenda C; Titó L; Martinez-Villacampa M; Vilella A; Xicola RM; Pons E; Llor X;
    Clin Gastroenterol Hepatol; 2008 Feb; 6(2):206-14. PubMed ID: 18096441
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Immunohistochemical staining for p16 and BRAFV600E is useful to distinguish between sporadic and hereditary (Lynch syndrome-related) microsatellite instable colorectal carcinomas.
    Boissière-Michot F; Frugier H; Ho-Pun-Cheung A; Lopez-Crapez E; Duffour J; Bibeau F
    Virchows Arch; 2016 Aug; 469(2):135-44. PubMed ID: 27220764
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Population-based screening for Lynch syndrome in Western Australia.
    Schofield L; Grieu F; Amanuel B; Carrello A; Spagnolo D; Kiraly C; Pachter N; Goldblatt J; Platell C; Levitt M; Stewart C; Salama P; Ee H; Raftopoulous S; Katris P; Threlfall T; Edkins E; Wallace M; Iacopetta B
    Int J Cancer; 2014 Sep; 135(5):1085-91. PubMed ID: 24474394
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Performance of tumor testing for Lynch syndrome identification in patients with colorectal cancer: A retrospective single-center study.
    Signoroni S; Tibiletti MG; Ricci MT; Milione M; Perrone F; Pensotti V; Chiaravalli AM; Carnevali I; Morabito A; Bertario L; Vitellaro M
    Tumori; 2019 Feb; 105(1):76-83. PubMed ID: 30117378
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Systematic immunohistochemical screening for Lynch syndrome in colorectal cancer: a single centre experience of 486 patients.
    Zumstein V; Vinzens F; Zettl A; Heinimann K; Koeberle D; von Flüe M; Bolli M
    Swiss Med Wkly; 2016; 146():w14315. PubMed ID: 27152634
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Population-based molecular screening for Lynch syndrome: implications for personalized medicine.
    Ward RL; Hicks S; Hawkins NJ
    J Clin Oncol; 2013 Jul; 31(20):2554-62. PubMed ID: 23733757
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A state-wide population-based program for detection of lynch syndrome based upon immunohistochemical and molecular testing of colorectal tumours.
    Schofield L; Grieu F; Goldblatt J; Amanuel B; Iacopetta B
    Fam Cancer; 2012 Mar; 11(1):1-6. PubMed ID: 22120844
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A practical screening strategy for Lynch syndrome and Lynch syndrome mimics in colorectal cancer.
    Yao ZG; Lv BB; Jing HY; Su WJ; Li JM; Fan H; Zhao MQ; Qin YJ; Sun XC
    J Cancer Res Ther; 2021 Jul; 17(3):790-796. PubMed ID: 34269315
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.